Eva Schaden1, Sibylle A Kozek-Langenecker. 1. Department of Anesthesiology, General Intensive Care and Pain Management, Medical University of Vienna, Währinger Guertel 18-20, 1090, Vienna, Austria. eva.schaden@meduniwien.ac.at
Abstract
PURPOSE: Anticoagulation is part of the daily routine of intensive care physicians. As the possibilities of pharmacological anticoagulation are becoming more numerous and diverse, intensive care physicians have to be familiar with indications, contraindications, dosing, and reversal of many different substances. This paper presents an overview of the substance group of direct thrombin inhibitors (DTI) indicated for alternative anticoagulation in intensive care medicine. METHODS: The review is a synopsis of scientific evidence, expert opinion, open forum commentary, and clinical feasibility data. RESULTS AND CONCLUSIONS: Due to their antithrombotic potential without direct activation of platelets, DTI could offer potential advantages over heparins and vitamin K antagonists in critically ill patients, especially regarding heparin-induced thrombocytopenia. Because of multiple organ dysfunction, organ failure, and comedications, simple extrapolation of results of medical to critically ill patients is not permissible. The fine line between thrombosis and bleeding in intensive care patients requires cautious dosing and close drug monitoring. Studies dealing with DTI in the intensive care setting are of utmost clinical interest.
PURPOSE: Anticoagulation is part of the daily routine of intensive care physicians. As the possibilities of pharmacological anticoagulation are becoming more numerous and diverse, intensive care physicians have to be familiar with indications, contraindications, dosing, and reversal of many different substances. This paper presents an overview of the substance group of direct thrombin inhibitors (DTI) indicated for alternative anticoagulation in intensive care medicine. METHODS: The review is a synopsis of scientific evidence, expert opinion, open forum commentary, and clinical feasibility data. RESULTS AND CONCLUSIONS: Due to their antithrombotic potential without direct activation of platelets, DTI could offer potential advantages over heparins and vitamin K antagonists in critically illpatients, especially regarding heparin-induced thrombocytopenia. Because of multiple organ dysfunction, organ failure, and comedications, simple extrapolation of results of medical to critically illpatients is not permissible. The fine line between thrombosis and bleeding in intensive care patients requires cautious dosing and close drug monitoring. Studies dealing with DTI in the intensive care setting are of utmost clinical interest.
Authors: Ignatius Y Tang; Donna S Cox; Kruti Patel; Bharathi V Reddy; Linda Nahlik; Sharon Trevino; Patrick T Murray Journal: Ann Pharmacother Date: 2005-01-04 Impact factor: 3.154
Authors: Jeanine M Walenga; Sarfraz Ahmad; Debra Hoppensteadt; Omer Iqbal; Marcie J Hursting; Bruce E Lewis Journal: Thromb Res Date: 2002-03-01 Impact factor: 3.944
Authors: Brian Y Hwang; Geoffrey Appelboom; Amit Ayer; Christopher P Kellner; Ivan S Kotchetkov; Paul R Gigante; Raqeeb Haque; Michael Kellner; E Sander Connolly Journal: Cerebrovasc Dis Date: 2010-12-21 Impact factor: 2.762
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2011-01-12 Impact factor: 17.440
Authors: Katie C T Riciluca; Ursula C Oliveira; Ronaldo Z Mendonça; José C Bozelli Junior; Shirley Schreier; Pedro I da Silva Junior Journal: FEBS Open Bio Date: 2021-08-19 Impact factor: 2.693